Last reviewed · How we verify
NCT05124379
Hemoclin Gel for the Treatment of Hemorrhoids
NA trial testing Hemoclin Gel in Hemorrhoids Grade I and II in 49 participants. Completed in 19 January 2022.
17 November 2021
Quick facts
| Lead sponsor | Karo Pharma AB |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 49 |
| Start date | 1 November 2021 |
| Primary completion | 17 November 2021 |
| Estimated completion | 19 January 2022 |
| Sites | 1 location across Poland |
Drugs / interventions tested
- Hemoclin Gel
Conditions studied
- Hemorrhoids Grade I and II — all drugs for Hemorrhoids Grade I and II →
Sponsor
Karo Pharma AB
Who can join
18 and older, any sex, with Hemorrhoids Grade I and II. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Post market, single arm, clinical investigation to assess safety and performance of the product.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05124379
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Karo Pharma AB trials
Trials by the same sponsor.
- NCT07233473 — Evaluation of the Effectiveness and Safety of a Vaginal Gel for Prevention of Recurrent Urinary Tract Infections · NA · recruiting
- NCT07234786 — Clinical Study of a Vaginal Gel for the Treatment and Prevention of Vaginal Infections · NA · recruiting
- NCT05552378 — Multi-Gyn FloraFem Study for Treatment of Vulvo Vaginal Candidiasis Symptoms · NA · completed
- NCT05732337 — Open Clinical Investigation to Evaluate the Effectiveness and Safety of a Topical Medical Device. · NA · completed
- NCT05560841 — Effectiveness and Safety of Nailner Brush 2in1 in Onychomycosis · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05124379 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Karo Pharma AB
- Last refreshed: 31 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05124379.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing